Abstract PD3-08: Effects of low dose tamoxifen on circulating risk biomarkers in a phase III trial in breast pre-invasive disease
Harriet Johansson(European Institute of Oncology), Andrea DeCensi(Memorial Sloan Kettering Cancer Center), Matteo Puntoni(University of Parma), Antonio Ponti(Piedmont Reference Center for Epidemiology and Cancer Prevention), Davide Serrano(European Institute of Oncology), Matteo Lazzeroni(European Institute of Oncology), Marcella Gulisano(Azienda Industriali Municipali di Vicenza (Italy)), C. Taverniti(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Tania Buttiron Webber(Ente Ospedaliero Ospedali Galliera), Valentina Aristarco(European Institute of Oncology), Fabio Falcini(Centro di Riferimento Oncologico), Maria Grazia Pacquola(Ospedale Sant Antonio), Laura Cortesi(Azienda Ospedaliero-Universitaria di Modena), Aliana Guerrieri‐Gonzaga(European Institute of Oncology), Bernardo Bonanni(European Institute of Oncology), Luca Boni(Ospedale Policlinico San Martino), Maria Digennaro, Anna Carriello(Azienda Unità Sanitaria Locale Della Romagna), Silvia Caviglia(Ente Ospedaliero Ospedali Galliera), Graziella Pinotti(Medica (Italy)), Debora Macis(European Institute of Oncology)
Cited by 2
Related Papers
Association analysis identifies 65 new breast cancer risk loci
|Nature|2017|1.6k
Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer
|Nature Medicine|2019|1.4k
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
|The American Journal of Human Genetics|2018|1.2k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k